30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Pharmaceuticals

Apellis Pharmaceuticals Inc (APLS)

Track

The most recent insider trading activity occurred on February 11, 2026, with a proposed sale by Officer Mark Jeffrey DeLong. Prior to this, on January 22, 2026, several executives, including the CEO, CFO, and CSO, engaged in significant sell transactions. These sales represent a notable pattern of insider divestment.
Stock chart
Ticker: APLS Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
DeLong Mark Jeffrey
Chief Business & Strat Officer
2 sales — total 16,305 USD
Sale 11 Feb 2026
Value US$2,112,541.11 | Price 449.09 | Shares 34,469
Proposed sale 11 Feb 2026
Value US$846,675.95 | Price 103.76 | Shares 82,637
Sale 22 Jan 2026
Value US$3,820,179.93 | Price 329.34 | Shares 98,173
Proposed sale 22 Jan 2026
Value US$439,980.97 | Price 269.16 | Shares 31,856
Sale 22 Jan 2026
Value US$73,371.16 | Price 21.77 | Shares 3,371
Proposed sale 22 Jan 2026
Value US$73,371.17 | Price 21.77 | Shares 3,371
Sale 22 Jan 2026
Value US$44,923.79 | Price 21.77 | Shares 2,064
Proposed sale 22 Jan 2026
Value US$44,923.79 | Price 21.77 | Shares 2,064
Sale 22 Jan 2026
Value US$60,877.82 | Price 21.77 | Shares 2,797
Proposed sale 22 Jan 2026
Value US$60,877.82 | Price 21.77 | Shares 2,797
Sale 22 Jan 2026
Value US$170,466.61 | Price 21.77 | Shares 7,832
Proposed sale 22 Jan 2026
Value US$170,466.61 | Price 21.77 | Shares 7,832
Sale 22 Jan 2026
Value US$223,900.67 | Price 21.77 | Shares 10,287
Proposed sale 22 Jan 2026
Value US$223,900.67 | Price 21.77 | Shares 10,287
Sale 22 Jan 2026
Value US$591,844.76 | Price 21.77 | Shares 27,192
Proposed sale 22 Jan 2026
Value US$591,844.76 | Price 21.77 | Shares 27,192
Sale 22 Jan 2026
Value US$168,137.72 | Price 21.77 | Shares 7,725
Proposed sale 22 Jan 2026
Value US$168,137.72 | Price 21.77 | Shares 7,725
Sale 20 Jan 2026
Value US$161,945.51 | Price 19.79 | Shares 8,182
Proposed sale 20 Jan 2026
Value US$161,945.51 | Price 19.79 | Shares 8,182
Sale 20 Jan 2026
Value US$57,241.07 | Price 19.79 | Shares 2,892
Proposed sale 20 Jan 2026
Value US$57,241.07 | Price 19.79 | Shares 2,892
Sale 20 Jan 2026
Value US$17,991.75 | Price 19.79 | Shares 909
Proposed sale 20 Jan 2026
Value US$17,991.75 | Price 19.79 | Shares 909
Sale 20 Jan 2026
Value US$43,603.76 | Price 19.79 | Shares 2,203
Proposed sale 20 Jan 2026
Value US$43,603.76 | Price 19.79 | Shares 2,203
Sale 20 Jan 2026
Value US$14,369.65 | Price 19.79 | Shares 726
Proposed sale 20 Jan 2026
Value US$14,369.65 | Price 19.79 | Shares 726
Sale 20 Jan 2026
Value US$26,403.73 | Price 19.79 | Shares 1,334
Proposed sale 20 Jan 2026
Value US$26,403.73 | Price 19.79 | Shares 1,334
Sale 20 Jan 2026
Value US$37,250.24 | Price 19.79 | Shares 1,882
Proposed sale 20 Jan 2026
Value US$37,250.24 | Price 19.79 | Shares 1,882
Sale 20 Jan 2026
Value US$48,987.43 | Price 19.79 | Shares 2,475
Proposed sale 20 Jan 2026
Value US$48,987.43 | Price 19.79 | Shares 2,475
Sale 13 Jan 2026
Value US$58,086.09 | Price 22.19 | Shares 2,618
Proposed sale 13 Jan 2026
Value US$58,086.09 | Price 22.19 | Shares 2,618
Sale 13 Jan 2026
Value US$19,369.43 | Price 22.19 | Shares 873
Proposed sale 13 Jan 2026
Value US$19,369.43 | Price 22.19 | Shares 873
Sale 13 Jan 2026
Value US$39,493.22 | Price 22.19 | Shares 1,780
Proposed sale 13 Jan 2026
Value US$39,493.22 | Price 22.19 | Shares 1,780
Sale 13 Jan 2026
Value US$225,998.82 | Price 22.19 | Shares 10,186
Proposed sale 13 Jan 2026
Value US$225,998.82 | Price 22.19 | Shares 10,186
Sale 13 Jan 2026
Value US$50,520.25 | Price 22.19 | Shares 2,277
Proposed sale 13 Jan 2026
Value US$50,520.25 | Price 22.19 | Shares 2,277
Sale 13 Jan 2026
Value US$128,242.02 | Price 22.19 | Shares 5,780
Proposed sale 13 Jan 2026
Value US$128,242.01 | Price 22.19 | Shares 5,780
Sale 13 Jan 2026
Value US$85,553.84 | Price 22.19 | Shares 3,856
Proposed sale 13 Jan 2026
Value US$85,553.84 | Price 22.19 | Shares 3,856
Sale 5 Jan 2026
Value US$77,096.67 | Price 25.53 | Shares 3,020
Proposed sale 5 Jan 2026
Value US$77,096.67 | Price 25.53 | Shares 3,020
Planned sale 16 Dec 2025
Value US$122,450.00 | Price 24.49 | Shares 5,000
Proposed sale 16 Dec 2025
Value US$122,450.00 | Price 24.49 | Shares 5,000
Planned sale 17 Nov 2025
Value US$100,300.00 | Price 20.06 | Shares 5,000
Proposed sale 17 Nov 2025
Value US$100,300.00 | Price 20.06 | Shares 5,000
Planned sale 21 Oct 2025
Value US$280,300.00 | Price 28.03 | Shares 10,000
Proposed sale 21 Oct 2025
Value US$280,300.00 | Price 28.03 | Shares 10,000
Planned sale 16 Oct 2025
Value US$126,100.00 | Price 25.22 | Shares 5,000
Proposed sale 16 Oct 2025
Value US$126,100.00 | Price 25.22 | Shares 5,000
Planned sale 10 Oct 2025
Value US$737,536.44 | Price 23.72 | Shares 31,092
Planned sale 30 Sep 2025
Value US$702,057.36 | Price 22.58 | Shares 31,092
Proposed sale 19 Sep 2025
Value US$2,140,917.00 | Price 22.95 | Shares 93,276
Planned sale 19 Sep 2025
Value US$713,561.40 | Price 22.95 | Shares 31,092
Planned sale 16 Sep 2025
Value US$121,700.00 | Price 24.34 | Shares 5,000
Proposed sale 16 Sep 2025
Value US$121,700.00 | Price 24.34 | Shares 5,000
Sale 15 Sep 2025
Value US$4,572.29 | Price 24.19 | Shares 189
Proposed sale 15 Sep 2025
Value US$4,572.29 | Price 24.19 | Shares 189
Sale 10 Sep 2025
Value US$523,400.00 | Price 26.17 | Shares 20,000
Proposed sale 10 Sep 2025
Value US$523,436.00 | Price 26.17 | Shares 20,000
Sale 8 Sep 2025
Value US$278,300.00 | Price 27.83 | Shares 10,000
Planned sale 8 Sep 2025
Value US$911,829.94 | Price 27.86 | Shares 32,729
Proposed sale 8 Sep 2025
Value US$911,829.94 | Price 27.86 | Shares 32,729
Proposed sale 8 Sep 2025
Value US$280,000.00 | Price 28.00 | Shares 10,000
Sale 2 Sep 2025
Value US$15,386.20 | Price 28.08 | Shares 548
Proposed sale 2 Sep 2025
Value US$15,386.20 | Price 28.08 | Shares 548
Sale 28 Aug 2025
Value US$1,418,449.57 | Price 28.39 | Shares 49,963
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-02-13 2026-02-11 S Sale
3.7
DeLong Mark Jeffrey

Chief Business & Strat Officer

Officer
34,469 +22.7%
449.09
US$2,112,541 		34,469 +22.7% 449.09 US$2,112,541
2026-02-11 2026-02-11 PrS Proposed sale
3.7
DeLong Mark Jeffrey

Officer

Officer
82,637
103.76
US$846,676 		82,637 103.76 US$846,676
2026-01-23 2026-01-22 S Sale
4.1
Deschatelets Pascal

Chief Scientific Officer

Officer
98,173 +13.6%
329.34
US$3,820,180 		98,173 +13.6% 329.34 US$3,820,180
2026-01-23 2026-01-22 S Sale
3.7
DeLong Mark Jeffrey

Chief Business & Strat Officer

Officer
3,371 -4.1%
21.77
US$73,371 		3,371 -4.1% 21.77 US$73,371
2026-01-23 2026-01-22 S Sale
3.6
Chopas James George

VP/Chief Accounting Officer

Officer
2,064 -4.0%
21.77
US$44,924 		2,064 -4.0% 21.77 US$44,924
2026-01-23 2026-01-22 S Sale
2.9
Baumal Caroline

Chief Medical Officer

Officer
2,797 -3.1%
21.77
US$60,878 		2,797 -3.1% 21.77 US$60,878
2026-01-23 2026-01-22 S Sale
3.4
Watson David O.

General Counsel

Officer
7,832 -8.1%
21.77
US$170,467 		7,832 -8.1% 21.77 US$170,467
2026-01-23 2026-01-22 S Sale
3.4
Sullivan Timothy Eugene

Chief Financial Officer

Officer
10,287 -9.9%
21.77
US$223,901 		10,287 -9.9% 21.77 US$223,901
2026-01-23 2026-01-22 S Sale
4.0
Francois Cedric

Chief Executive Officer

Executive Director
27,192 -8.7%
21.77
US$591,845 		27,192 -8.7% 21.77 US$591,845
2026-01-23 2026-01-22 S Sale
3.1
Nicholson Nur

Chief Technical Officer

Officer
7,725 -9.8%
21.77
US$168,138 		7,725 -9.8% 21.77 US$168,138
2026-01-22 2026-01-22 PrS Proposed sale
3.4
Watson David O.

Officer

Officer
7,832
21.77
US$170,467 		7,832 21.77 US$170,467
2026-01-22 2026-01-22 PrS Proposed sale
4.1
Deschatelets Pascal

Officer

Officer
5,928
21.77
US$129,025 		5,928 21.77 US$129,025
2026-01-22 2026-01-22 PrS Proposed sale
3.4
Sullivan Timothy Eugene

Officer

Officer
10,287
21.77
US$223,901 		10,287 21.77 US$223,901
2026-01-22 2026-01-22 PrS Proposed sale
3.7
DeLong Mark Jeffrey

Officer

Officer
3,371
21.77
US$73,371 		3,371 21.77 US$73,371
2026-01-22 2026-01-22 PrS Proposed sale
4.0
Francois Cedric

Officer

Officer
27,192
21.77
US$591,845 		27,192 21.77 US$591,845
2026-01-22 2026-01-22 PrS Proposed sale
3.1
Nicholson Nur

Officer

Officer
7,725
21.77
US$168,138 		7,725 21.77 US$168,138
2026-01-22 2026-01-22 PrS Proposed sale
3.6
Chopas James George

Officer

Officer
2,064
21.77
US$44,924 		2,064 21.77 US$44,924
2026-01-22 2026-01-22 PrS Proposed sale
2.9
Baumal Caroline

Officer

Officer
2,797
21.77
US$60,878 		2,797 21.77 US$60,878
2026-01-21 2026-01-20 S Sale
4.0
Francois Cedric

Chief Executive Officer

Executive Director
8,182 -2.5%
19.79
US$161,946 		8,182 -2.5% 19.79 US$161,946
2026-01-21 2026-01-20 S Sale
3.4
Sullivan Timothy Eugene

Chief Financial Officer

Officer
2,892 -2.7%
19.79
US$57,241 		2,892 -2.7% 19.79 US$57,241
2026-01-21 2026-01-20 S Sale
4.1
Deschatelets Pascal

Chief Scientific Officer

Officer
909 -0.1%
19.79
US$17,992 		909 -0.1% 19.79 US$17,992
2026-01-21 2026-01-20 S Sale
3.1
Nicholson Nur

Chief Technical Officer

Officer
2,203 -2.7%
19.79
US$43,604 		2,203 -2.7% 19.79 US$43,604
2026-01-21 2026-01-20 S Sale
3.6
Chopas James George

VP/Chief Accounting Officer

Officer
726 -1.4%
19.79
US$14,370 		726 -1.4% 19.79 US$14,370
2026-01-21 2026-01-20 S Sale
3.7
DeLong Mark Jeffrey

Chief Business & Strat Officer

Officer
1,334 -1.6%
19.79
US$26,404 		1,334 -1.6% 19.79 US$26,404
2026-01-21 2026-01-20 S Sale
2.9
Baumal Caroline

Chief Medical Officer

Officer
1,882 -2.1%
19.79
US$37,250 		1,882 -2.1% 19.79 US$37,250
2026-01-21 2026-01-20 S Sale
3.4
Watson David O.

General Counsel

Officer
2,475 -2.5%
19.79
US$48,987 		2,475 -2.5% 19.79 US$48,987
2026-01-20 2026-01-20 PrS Proposed sale
3.1
Nicholson Nur

Officer

Officer
2,203
19.79
US$43,604 		2,203 19.79 US$43,604
2026-01-20 2026-01-20 PrS Proposed sale
3.4
Watson David O.

Officer

Officer
2,475
19.79
US$48,987 		2,475 19.79 US$48,987
2026-01-20 2026-01-20 PrS Proposed sale
4.0
Francois Cedric

Officer

Officer
8,182
19.79
US$161,946 		8,182 19.79 US$161,946
2026-01-20 2026-01-20 PrS Proposed sale
3.7
DeLong Mark Jeffrey

Officer

Officer
1,334
19.79
US$26,404 		1,334 19.79 US$26,404
2026-01-20 2026-01-20 PrS Proposed sale
4.1
Deschatelets Pascal

Officer

Officer
909
19.79
US$17,992 		909 19.79 US$17,992
2026-01-20 2026-01-20 PrS Proposed sale
2.9
Baumal Caroline

Officer

Officer
1,882
19.79
US$37,250 		1,882 19.79 US$37,250
2026-01-20 2026-01-20 PrS Proposed sale
3.4
Sullivan Timothy Eugene

Officer

Officer
2,892
19.79
US$57,241 		2,892 19.79 US$57,241
2026-01-20 2026-01-20 PrS Proposed sale
3.6
Chopas James George

Officer

Officer
726
19.79
US$14,370 		726 19.79 US$14,370
2026-01-15 2026-01-13 S Sale
3.1
Nicholson Nur

Chief Technical Officer

Officer
2,618 -3.1%
22.19
US$58,086 		2,618 -3.1% 22.19 US$58,086
2026-01-15 2026-01-13 S Sale
3.6
Chopas James George

VP/Chief Accounting Officer

Officer
873 -1.6%
22.19
US$19,369 		873 -1.6% 22.19 US$19,369
2026-01-15 2026-01-13 S Sale
3.7
DeLong Mark Jeffrey

Chief Business & Strat Officer

Officer
1,780 -2.1%
22.19
US$39,493 		1,780 -2.1% 22.19 US$39,493
2026-01-15 2026-01-13 S Sale
4.0
Francois Cedric

Chief Executive Officer

Executive Director
10,186 -3.1%
22.19
US$225,999 		10,186 -3.1% 22.19 US$225,999
2026-01-15 2026-01-13 S Sale
4.1
Deschatelets Pascal

Chief Scientific Officer

Officer
2,277 -0.2%
22.19
US$50,520 		2,277 -0.2% 22.19 US$50,520
2026-01-15 2026-01-13 S Sale
3.4
Watson David O.

General Counsel

Officer
5,780 -5.5%
22.19
US$128,242 		5,780 -5.5% 22.19 US$128,242
2026-01-15 2026-01-13 S Sale
3.4
Sullivan Timothy Eugene

Chief Financial Officer

Officer
3,856 -3.5%
22.19
US$85,554 		3,856 -3.5% 22.19 US$85,554
2026-01-13 2026-01-13 PrS Proposed sale
3.1
Nicholson Nur

Officer

Officer
2,618
22.19
US$58,086 		2,618 22.19 US$58,086
2026-01-13 2026-01-13 PrS Proposed sale
3.6
Chopas James George

Officer

Officer
873
22.19
US$19,369 		873 22.19 US$19,369
2026-01-13 2026-01-13 PrS Proposed sale
3.4
Watson David O.

Officer

Officer
5,780
22.19
US$128,242 		5,780 22.19 US$128,242
2026-01-13 2026-01-13 PrS Proposed sale
3.7
DeLong Mark Jeffrey

Officer

Officer
1,780
22.19
US$39,493 		1,780 22.19 US$39,493
2026-01-13 2026-01-13 PrS Proposed sale
4.1
Deschatelets Pascal

Officer

Officer
2,277
22.19
US$50,520 		2,277 22.19 US$50,520
2026-01-13 2026-01-13 PrS Proposed sale
4.0
Francois Cedric

Officer; Director

Executive Director
10,186
22.19
US$225,999 		10,186 22.19 US$225,999
2026-01-13 2026-01-13 PrS Proposed sale
3.4
Sullivan Timothy Eugene

Officer

Officer
3,856
22.19
US$85,554 		3,856 22.19 US$85,554
2026-01-06 2026-01-05 S Sale
2.9
Baumal Caroline

Chief Medical Officer

Officer
3,020 -3.2%
25.53
US$77,097 		3,020 -3.2% 25.53 US$77,097
2026-01-05 2026-01-05 PrS Proposed sale
2.9
Baumal Caroline

Officer

Officer
3,020
25.53
US$77,097 		3,020 25.53 US$77,097
2025-12-18 2025-12-16 PlS Planned sale
3.4
Watson David O.

General Counsel

Officer
5,000 -4.6%
24.49
US$122,450 		5,000 -4.6% 24.49 US$122,450
2025-12-16 2025-12-16 PrS Proposed sale
3.4
Watson David O.

Officer

Officer
5,000
24.49
US$122,450 		5,000 24.49 US$122,450
2025-11-18 2025-11-17 PlS Planned sale
3.4
Watson David O.

General Counsel

Officer
5,000 -4.4%
20.06
US$100,300 		5,000 -4.4% 20.06 US$100,300
2025-11-17 2025-11-17 PrS Proposed sale
3.4
Watson David O.

Officer

Officer
5,000
20.06
US$100,300 		5,000 20.06 US$100,300
2025-10-23 2025-10-21 PlS Planned sale
3.4
Sullivan Timothy Eugene

Chief Financial Officer

Officer
10,000 -8.3%
28.03
US$280,300 		10,000 -8.3% 28.03 US$280,300
2025-10-21 2025-10-21 PrS Proposed sale
3.4
Sullivan Timothy Eugene

Officer

Officer
10,000
28.03
US$280,300 		10,000 28.03 US$280,300
2025-10-17 2025-10-16 PlS Planned sale
3.4
Watson David O.

General Counsel

Officer
5,000 -4.2%
25.22
US$126,100 		5,000 -4.2% 25.22 US$126,100
2025-10-16 2025-10-16 PrS Proposed sale
3.4
Watson David O.

Officer

Officer
5,000
25.22
US$126,100 		5,000 25.22 US$126,100
2025-10-15 2025-10-10 PlS Planned sale
3.1
Dunlop A. Sinclair
Non-Executive Director
31,092 -89.0%
23.72
US$737,536 		31,092 -89.0% 23.72 US$737,536
2025-10-02 2025-09-30 PlS Planned sale
3.1
Dunlop A. Sinclair
Non-Executive Director
31,092 -47.8%
22.58
US$702,057 		31,092 -47.8% 22.58 US$702,057
2025-09-19 2025-09-19 PrS Proposed sale
3.1
Dunlop A. Sinclair

Director

Non-Executive Director
93,276
22.95
US$2,140,917 		93,276 22.95 US$2,140,917
2025-09-19 2025-09-19 PlS Planned sale
3.1
Dunlop A. Sinclair
Non-Executive Director
31,092 -31.1%
22.95
US$713,561 		31,092 -31.1% 22.95 US$713,561
2025-09-18 2025-09-16 PlS Planned sale
3.4
Watson David O.

General Counsel

Officer
5,000 -4.0%
24.34
US$121,700 		5,000 -4.0% 24.34 US$121,700
2025-09-16 2025-09-16 PrS Proposed sale
3.4
Watson David O.

Officer

Officer
5,000
24.34
US$121,700 		5,000 24.34 US$121,700
2025-09-17 2025-09-15 S Sale
3.6
Chopas James George

VP/Chief Accounting Officer

Officer
189 -0.4%
24.19
US$4,572 		189 -0.4% 24.19 US$4,572
2025-09-15 2025-09-15 PrS Proposed sale
3.6
Chopas James George

Officer

Officer
189
24.19
US$4,572 		189 24.19 US$4,572
2025-09-12 2025-09-10 S Sale
3.4
Watson David O.

General Counsel

Officer
20,000 -28.5%
26.17
US$523,400 		20,000 -28.5% 26.17 US$523,400
2025-09-10 2025-09-10 PrS Proposed sale
3.4
THE DAVID O WATSON IRREV TR OF 2023

Officer

Officer
20,000
26.17
US$523,436 		20,000 26.17 US$523,436
2025-09-10 2025-09-08 S Sale
3.4
Sullivan Timothy Eugene

Chief Financial Officer

Officer
10,000 -14.2%
27.83
US$278,300 		10,000 -14.2% 27.83 US$278,300
2025-09-10 2025-09-08 PlS Planned sale
3.4
Sullivan Timothy Eugene

Chief Financial Officer

Officer
32,729 -22.8%
27.86
US$911,830 		32,729 -22.8% 27.86 US$911,830
2025-09-08 2025-09-08 PrS Proposed sale
3.4
Timothy E Sullivan Irrevocable Trust of 2023 DTD 03/30/2023

Officer

Officer
10,000
28.00
US$280,000 		10,000 28.00 US$280,000
2025-09-08 2025-09-08 PrS Proposed sale
3.4
Sullivan Timothy Eugene

Officer

Officer
32,729
27.86
US$911,830 		32,729 27.86 US$911,830
2025-09-03 2025-09-02 S Sale
3.6
Chopas James George

VP/Chief Accounting Officer

Officer
548 -1.0%
28.08
US$15,386 		548 -1.0% 28.08 US$15,386
2025-09-02 2025-09-02 PrS Proposed sale
3.6
Chopas James George

Officer

Officer
548
28.08
US$15,386 		548 28.08 US$15,386
2025-08-29 2025-08-28 S Sale
4.0
Francois Cedric

Chief Executive Officer

Executive Director
49,963 -14.0%
28.39
US$1,418,450 		49,963 -14.0% 28.39 US$1,418,450
Explore more

More insider trading research around Apellis Pharmaceuticals Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Pharmaceuticals companies with insider activity
Insider trading in North America